Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03017131
Title Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute

ovarian carcinoma

fallopian tube carcinoma

peritoneal carcinoma


Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.